Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 1/20 | 0.45 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.45 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 7/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.36 |
| ▸ | MBOAT4 | Q96T53 | 3/20 | 0.34 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL994647 | 0.87 | CDK5 (0.49) | CDK5CDK5R1NR1I3GRIN1GRIN2B | |
| SCHEMBL536894 | 0.87 | CDK5 (0.49) | CDK5CDK5R1NR1I3GRIN1GRIN2B | |
| SCHEMBL994646 | 0.87 | CDK5 (0.49) | CDK5CDK5R1NR1I3GRIN1GRIN2B | |
| SCHEMBL157803 | 0.75 | CDK5 (0.64) | CDK5CDK5R1NR1I3GRIN1GRIN2B | |
| SCHEMBL10343473 | 0.75 | CDK5 (0.64) | CDK5CDK5R1NR1I3GRIN1GRIN2B | |
| SCHEMBL24451237 | 0.75 | CDK5 (0.64) | CDK5CDK5R1NR1I3GRIN1GRIN2B | |
| SCHEMBL30331615 | 0.75 | CDK5 (0.64) | CDK5CDK5R1NR1I3GRIN1GRIN2B | |
| SCHEMBL4998832 | 0.75 | CDK5 (0.64) | CDK5CDK5R1NR1I3GRIN1GRIN2B | |
| SCHEMBL317924 | 0.75 | CDK5 (0.64) | CDK5CDK5R1NR1I3GRIN1GRIN2B | |
| SCHEMBL157802 | 0.75 | CDK5 (0.64) | CDK5CDK5R1NR1I3GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9611270-B2 | Inhibitors of CYP17A1 | UNIVERSITY OF KANSAS (US) | 2017-04-04 | — | — | US | disclosed |
| US-20160031929-A1 | INHIBITORS OF CYP17A1 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031929-A1 | INHIBITORS OF CYP17A1 | CYP19A1, CYP17A1, CYP21A2 | CDK5 1036/4885CDK5R1 455/4885NR1I3 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.